Clinical Competition Candidate
ORACEA
ORACEA carries product and use-code patents, low complexity (1/5), and meaningful clinical competition (5/5). The listed expiry window is approximately 17 months away. Active clinical competition may compress the generic entry window.
LOE window
17months
to latest listed patent expiry (December 19, 2027)
Expiry attractiveness: 4/5
Patent profile
Substance patent (none)
Product / formulation patent (listed)
Use-code patent (listed)
Patent count: 1
Complexity score: 1/5
Clinical competition
Score: 5/5
Active trials linked: 300
Phase 2/3 trials: 134
Higher scores indicate more trial activity for this ingredient — a proxy for competitive generic interest.
Drug overview
Active ingredient: DOXYCYCLINE
Applicant (NDA holder): GALDERMA LABORATORIES LP
Confidence: High